文献速递眼底病与葡萄膜炎

玻璃体腔注射阿柏西普与雷珠单抗治疗亚洲新生血管性年龄相关性黄斑变性患者的疗效与安全性:VIEW试验亚组分析

EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB IN ASIAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Subgroup Analyses From the VIEW Trials.
PubMed 文献 · Retina · 2019-01-01

基于VIEW 1和VIEW 2试验,评估亚洲新生血管性年龄相关性黄斑变性患者(n=269)接受玻璃体腔注射阿柏西普2q4或2q8与雷珠单抗0.5 mg每月治疗的疗效与安全性,并与白人患者(n=2044)比较。第96周时,阿柏西普与雷珠单抗在最佳矫正视力平均增益上无显著差异,阿柏西普2q4和2q8在中央视网膜厚度降低及干性视网膜比例上优于雷珠单抗,亚洲与白人患者结局无差异。

要点

  • 亚洲患者中,阿柏西普2q4和2q8与雷珠单抗在最佳矫正视力平均增益上无显著差异。
  • 阿柏西普2q4和2q8的中央视网膜厚度降低幅度大于雷珠单抗。
  • 阿柏西普2q4的干性视网膜比例高于雷珠单抗,亚洲与白人患者结局无差异。

核心结论

  • 在亚洲新生血管性年龄相关性黄斑变性患者中,阿柏西普与雷珠单抗组的功能和形态学结局基本相似,且与白人患者所见结果相似。

研究设计与样本

  • 评估VIEW 1和VIEW 2试验数据,比较亚洲患者(n=269)及亚洲与白人患者(n=2044)第96周的功能和形态学结局。

主要发现

  • 亚洲患者中,阿柏西普2q4和2q8与雷珠单抗的最佳矫正视力平均增益分别为10.23和8.35 vs 8.51个字母,无显著差异。
  • 亚洲患者中,阿柏西普2q4(150.43 μm,P=0.0075)和2q8(148.15 μm,P=0.0126)的中央视网膜厚度降低大于雷珠单抗(119.46 μm)。
  • 亚洲患者中,阿柏西普2q4的干性视网膜比例为65.7%(P<0.01),高于雷珠单抗的41.7%。
  • 亚洲与白人患者之间的结局无差异。
  • 严重治疗中出现眼部不良事件发生在<8%的治疗眼中,在各亚组间分布均匀。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the treatment effect of intravitreal aflibercept and ranibizumab in Asian patients with neovascular age-related macular degeneration. METHODS: We evaluated data from VIEW 1 and VIEW 2, comparing functional and morphologic outcomes at Week 96 between intravitreal aflibercept 2 mg monthly (2q4) or 2 mg bimonthly after 3 initial monthly doses (2q8) versus ranibizumab 0.5 mg monthly among Asian patients (n = 269) and between Asian and white patients (n = 2044). RESULTS: In Asian patients, there were no significant differences between intravitreal aflibercept 2q4 and 2q8 compared with ranibizumab in mean gain in best-corrected visual acuity (10.23 and 8.35 vs. 8.51 letters). Reduction in central retinal thickness was greater for intravitreal aflibercept 2q4 (150.43 μm, P = 0.0075) and 2q8 (148.15 μm, P = 0.0126) than ranibizumab (119.46 μm). The proportion of dry retinas was greater for intravitreal aflibercept 2q4 (65.7%, P < 0.01) than ranibizumab (41.7%). There were no differences in outcomes between Asian and white patients. Serious treatment-emergent ocular adverse events occurred in <8% of treated eyes, evenly distributed across subgroups. CONCLUSION: In Asian patients with neovascular age-related macular degeneration, functional and morphologic outcomes were largely similar between intravitreal aflibercept and ranibizumab groups, and to results seen in white patients.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Wong TY, Cheung CMG, Lai TYY, et al. EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT AND RANIBIZUMAB IN ASIAN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Subgroup Analyses From the VIEW Trials. Retina. 2019. PMID: 29280937. doi:10.1097/IAE.0000000000001986

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。